Drugs

AgeX & Juvenescence closer to universal allogeneic cells

AgeX and Juvenescence publish progress in development of hypoimmunogenic cells. Longevity focused life sciences companies, AgeX Therapeutics and Juvenescence , today announced the publication...

Dogs or mice? Our exclusive with Dr Steven Austad

If we're going to find robust solutions for aging, we may need more than mouse models — argues the University of Alabama at Birmingham's...

Biogen’s Alzheimer’s drug is back from the dead

From Biogen, the first drug to actually slow the decline of Alzheimer's disease, rather than just ameliorate the symptoms, is alive and seeking FDA...

Deep dive report: From mice to men

Mouse models used for research in aging therapies can only go so far in progressing human Longevity. Longevity.Technology: In this deep dive report we talk with experienced...

Latest articles

UK doctors told to ignore consumer genetic tests

Royal College of General Practitioners guidance places significant doubt on consumer genetic testing. Consumer interest in genetic testing has grown in popularity in recent years,...

New study shows rapamycin slows Alzheimer’s

A new study from UT Health San Antonio suggests the drug rapamycin may be able to slow the rate of brain-related blood flow decreases. The...

Meet the Startup: Kintell’s take on Alexa Skills

New IoT device focuses on prolonging independence for the broader aging population. While there are many technologies out there designed to help older people who...

The Longevity Week: Addressing global Longevity

A packed week of multidisciplinary events with a global focus on the Longevity challenge. One year ago, the first Longevity Forum event was held in...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.